|
1.
|
Matzku S, Wenzel A, Liu S and Zoller M:
Antigenic differences between metastatic and nonmetastatic BSp73
rat tumor variants characterized by monoclonal antibodies. Cancer
Res. 49:1294–1299. 1989.PubMed/NCBI
|
|
2.
|
Claas C, Herrmann K, Matzku S, Moller P
and Zoller M: Developmentally regulated expression of
metastasis-associated antigens in the rat. Cell Growth Differ.
7:663–678. 1996.PubMed/NCBI
|
|
3.
|
Rosel M, Claas C, Seiter S, Herlevsen M
and Zoller M: Cloning and functional characterization of a new
phosphatidyl-inositol anchored molecule of a metastasizing rat
pancreatic tumor. Oncogene. 17:1989–2002. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Wurfel J, Seiter S, Stassar M, et al:
Cloning of the human homologue of the metastasis-associated rat
C4.4A. Gene. 262:35–41. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Smith BA, Kennedy WJ, Harnden P, Selby PJ,
Trejdosiewicz LK and Southgate J: Identification of genes involved
in human urothelial cell-matrix interactions: implications for the
progression pathways of malignant urothelium. Cancer Res.
61:1678–1685. 2001.PubMed/NCBI
|
|
6.
|
Hansen LV, Gardsvoll H, Nielsen BS, et al:
Structural analysis and tissue localization of human C4.4A: a
protein homologue of the urokinase receptor. Biochem J.
380:845–857. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Konishi K, Yamamoto H, Mimori K, et al:
Expression of C4.4A at the invasive front is a novel prognostic
marker for disease recurrence of colorectal cancer. Cancer Sci.
101:2269–2277. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Oshiro R, Yamamoto H, Takahashi H, et al:
C4.4A is associated with tumor budding and epithelial-mesenchymal
transition of colorectal cancer. Cancer Sci. 103:1155–1164. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Yamamoto H, Oshiro R, Ohtsuka M, et al:
Distinct expression of C4.4A in colorectal cancer detected by
different antibodies. Int J Oncol. 42:197–201. 2013.
|
|
10.
|
Ohtsuka M, Yamamoto H, Masuzawa T, et al:
C4.4A is associated with a poor prognosis of esophageal squamous
cell carcinoma. Ann Surg Oncol. Feb 24–2013.(Epub ahead of
print).
|
|
11.
|
Beiter K, Hiendlmeyer E, Brabletz T, et
al: beta-catenin regulates the expression of tenascin-C in human
colorectal tumors. Oncogene. 24:8200–8204. 2005.PubMed/NCBI
|
|
12.
|
Oskarsson T, Acharyya S, Zhang XH, et al:
Breast cancer cells produce tenascin C as a metastatic niche
component to colonize the lungs. Nat Med. 17:867–874. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Nagaharu K, Zhang X, Yoshida T, et al:
Tenascin C induces epithelial-mesenchymal transition-like change
accompanied by SRC activation and focal adhesion kinase
phosphorylation in human breast cancer cells. Am J Pathol.
178:754–763. 2011. View Article : Google Scholar
|
|
14.
|
O’Connell JT, Sugimoto H, Cooke VG, et al:
VEGF-A and Tenascin-C produced by S100A4+ stromal cells
are important for metastatic colonization. Proc Natl Acad Sci USA.
108:16002–16007. 2011.
|
|
15.
|
Orend G and Chiquet-Ehrismann R:
Tenascin-C induced signaling in cancer. Cancer Lett. 244:143–163.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
De Wever O, Nguyen QD, Van Hoorde L, et
al: Tenascin-C and SF/HGF produced by myofibroblasts in vitro
provide convergent pro-invasive signals to human colon cancer cells
through RhoA and Rac. FASEB J. 18:1016–1018. 2004.PubMed/NCBI
|
|
17.
|
Sarkar S, Nuttall RK, Liu S, Edwards DR
and Yong VW: Tenascin-C stimulates glioma cell invasion through
matrix metalloproteinase-12. Cancer Res. 66:11771–11780. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Hirata E, Arakawa Y, Shirahata M, et al:
Endogenous tenascin-C enhances glioblastoma invasion with reactive
change of surrounding brain tissue. Cancer Sci. 100:1451–1459.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Fukunaga-Kalabis M, Martinez G, Nguyen TK,
et al: Tenascin-C promotes melanoma progression by maintaining the
ABCB5-positive side population. Oncogene. 29:6115–6124. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Sjoquist KM, Burmeister BH, Smithers BM,
et al: Survival after neoadjuvant chemotherapy or chemoradiotherapy
for resectable oesophageal carcinoma: an updated meta-analysis.
Lancet Oncol. 12:681–692. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Stahl M, Walz MK, Stuschke M, et al: Phase
III comparison of preoperative chemotherapy compared with
chemoradiotherapy in patients with locally advanced adenocarcinoma
of the esophagogastric junction. J Clin Oncol. 27:851–856. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Ando N, Kato H, Igaki H, et al: A
randomized trial comparing postoperative adjuvant chemotherapy with
cisplatin and 5-fluorouracil versus preoperative chemotherapy for
localized advanced squamous cell carcinoma of the thoracic
esophagus (JCOG9907). Ann Surg Oncol. 19:68–74. 2012. View Article : Google Scholar
|
|
23.
|
Yamamoto H, Kondo M, Nakamori S, et al:
JTE-522, a cyclooxygenase-2 inhibitor, is an effective
chemopreventive agent against rat experimental liver fibrosis1.
Gastroenterology. 125:556–571. 2003.PubMed/NCBI
|
|
24.
|
Hayashi N, Yamamoto H, Hiraoka N, et al:
Differential expression of cyclooxygenase-2 (COX-2) in human bile
duct epithelial cells and bile duct neoplasm. Hepatology.
34:638–650. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Noura S, Yamamoto H, Ohnishi T, et al:
Comparative detection of lymph node micrometastases of stage II
colorectal cancer by reverse transcriptase polymerase chain
reaction and immunohistochemistry. J Clin Oncol. 20:4232–4241.
2002. View Article : Google Scholar
|
|
26.
|
Ferlay J, Shin H-R, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Holmes RS and Vaughan TL: Epidemiology and
pathogenesis of esophageal cancer. Semin Radiat Oncol. 17:2–9.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Pas J, Wyszko E, Rolle K, et al: Analysis
of structure and function of tenascin-C. Int J Biochem Cell Biol.
38:1594–1602. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Jones FS and Jones PL: The tenascin family
of ECM glyco-proteins: structure, function and regulation during
embryonic development and tissue remodeling. Dev Dyn. 218:235–259.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Chiquet-Ehrismann R, Kalla P and Pearson
CA: Participation of tenascin and transforming growth factor-beta
in reciprocal epithelial-mesenchymal interactions of MCF7 cells and
fibroblasts. Cancer Res. 49:4322–4325. 1989.PubMed/NCBI
|
|
31.
|
Orend G and Chiquet-Ehrismann R: Adhesion
modulation by antiadhesive molecules of the extracellular matrix.
Exp Cell Res. 261:104–110. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Villuendas R, Steegmann JL, Pollan M, et
al: Identification of genes involved in imatinib resistance in CML:
a gene-expression profiling approach. Leukemia. 20:1047–1054. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Helleman J, Jansen MP, Ruigrok-Ritstier K,
et al: Association of an extracellular matrix gene cluster with
breast cancer prognosis and endocrine therapy response. Clin Cancer
Res. 14:5555–5564. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Calvo A, Catena R, Noble MS, et al:
Identification of VEGF-regulated genes associated with increased
lung metastatic potential: functional involvement of tenascin-C in
tumor growth and lung metastasis. Oncogene. 27:5373–5384. 2008.
View Article : Google Scholar : PubMed/NCBI
|
